O Moradi1, I Karimzadeh2, D Davani-Davari2, M Shafiekhani2, M M Sagheb3, G A Raees-Jalali3. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. 3. Nephrology-Urology Research Center and Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
BACKGROUND: Number of patients undergoing kidney transplantation is ever increasing. Drug-drug interactions (DDIs) can complicate transplant patient's treatment course. OBJECTIVE: To investigate patterns and factors associated with potential DDIs in kidney transplant recipients under maintenance immunosuppressive regimen at a referral transplantation center in Shiraz, Iran. METHODS: 390 eligible kidney transplant outpatients referred to Motahhari clinic and one of the attending nephrologist's private office during an18-month period were assessed for DDIs. Using the Lexi-Interact online drug interactions software, the prescribed drugs were assessed for the number and type of potential DDIs. Only type D and X interactions were considered eligible for inclusion. RESULTS: During the study period, 344 DDIs were detected of which, 290 were type D; 54 were type XDDIs. 81% of the detected DDIs were pharmacokinetics. Interaction between cyclosporine + mycophenolic acid (32.3%) was the most frequent DDIs followed by cyclosporine + atorvastatin (11.3%). Immunosuppressant (43.44%) was the most frequently used medication responsible for DDIs. Number of co-administered medications (OR: 1.34, 95% CI: 1.12-1.51) and cyclosporine as main immunosuppressive main drug (OR: 10.43, 95% CI: 6.24-17.42) were identified as independent risk factors for DDIs. CONCLUSION: Major DDIs were common in kidney transplant recipients. Considering the importance of DDIs in kidney transplant patients, more attention is warranted in this regard by health care members, especially physicians and pharmacists.
BACKGROUND: Number of patients undergoing kidney transplantation is ever increasing. Drug-drug interactions (DDIs) can complicate transplant patient's treatment course. OBJECTIVE: To investigate patterns and factors associated with potential DDIs in kidney transplant recipients under maintenance immunosuppressive regimen at a referral transplantation center in Shiraz, Iran. METHODS: 390 eligible kidney transplant outpatients referred to Motahhari clinic and one of the attending nephrologist's private office during an18-month period were assessed for DDIs. Using the Lexi-Interact online drug interactions software, the prescribed drugs were assessed for the number and type of potential DDIs. Only type D and X interactions were considered eligible for inclusion. RESULTS: During the study period, 344 DDIs were detected of which, 290 were type D; 54 were type XDDIs. 81% of the detected DDIs were pharmacokinetics. Interaction between cyclosporine + mycophenolic acid (32.3%) was the most frequent DDIs followed by cyclosporine + atorvastatin (11.3%). Immunosuppressant (43.44%) was the most frequently used medication responsible for DDIs. Number of co-administered medications (OR: 1.34, 95% CI: 1.12-1.51) and cyclosporine as main immunosuppressive main drug (OR: 10.43, 95% CI: 6.24-17.42) were identified as independent risk factors for DDIs. CONCLUSION: Major DDIs were common in kidney transplant recipients. Considering the importance of DDIs in kidney transplant patients, more attention is warranted in this regard by health care members, especially physicians and pharmacists.
Entities:
Keywords:
Drug interactions; Immunosuppressive agents; Kidney transplantation; Outpatients
Authors: Paulino Antonio Alvarez; Jose Egozcue; Jihan Sleiman; Lucas Moretti; Guillermo Di Girolamo; Guillermo Alberto Keller Journal: Curr Drug Saf Date: 2012-02
Authors: Bernhard K Krämer; Giuseppe Montagnino; Domingo Del Castillo; Raimund Margreiter; Heide Sperschneider; Christoph J Olbricht; Bernd Krüger; Joaquín Ortuño; Hans Köhler; Ulrich Kunzendorf; Hans-Krister Stummvoll; Jose M Tabernero; Ferdinand Mühlbacher; Manuel Rivero; Manuel Arias Journal: Nephrol Dial Transplant Date: 2005-03-01 Impact factor: 5.992
Authors: M M R de Maat; A de Boer; C H W Koks; J W Mulder; P L Meenhorst; E C M van Gorp; A T A Mairuhu; A D R Huitema; J H Beijnen Journal: J Clin Pharm Ther Date: 2004-04 Impact factor: 2.512